Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

2024818 citationsJournal Articlegreen Open Access

Authors

Thomas Powles · Queen Mary University of London

Begoña P. Valderrama · Hospital Universitario Virgen del Rocío

Shilpa Gupta · Cleveland Clinic

Jens Bedke · Katharinenhospital

Eiji Kikuchi · St. Marianna University School of Medicine

Jean Hoffman‐Censits · Sidney Kimmel Comprehensive Cancer Center

Gopa Iyer

Abstract

Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).

Topics & Keywords

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Esophageal Cancer Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 390, Issue 10, pp. 875-888

DOI: 10.1056/nejmoa2312117

Field-Weighted Citation Impact: 461.32